The National Vaccine Injusty Compensation Program (VICP) was introduced through the National Childhood Vaccine Injury Act of 1986 to compensate individuals who experience severe adverse effects from an eligible vaccine. The program was intended to decrease vaccine hesitancy caused by alleged severe adverse effects in children who received the diphtheria-tetanus-pertussis (DTaP) vaccine.1
Although only 18 of 15,752 DTaP recipients in findings from a 1981 study experienced serious reactions, the media capitalized on the conspiracy by presenting stories of affected children in documentaries such as DPT: Vaccine Roulette from 1982 or inviting celebrities to discuss and promote vaccine avoidance.2,3 Behaviors such as these caused disruptions in vaccine distribution pipelines and hindered completion of necessary vaccination schemes. Considering the threat that an increasingly unvaccinated population posed to national health, stakeholders appealed to the US Congress hoping for the establishment of a nationwide program to compensate individuals for injuries related to vaccines or their administration.1
To claim compensation for a vaccination-related injury, a patient must file a petition by submitting a cover sheet along with relevant medical records to the US Court of Federal Claims and the Division of Injury Compensation Programs. Anyone who has experienced a severe adverse effect from an eligible vaccine and is within the accepted time frame can file a claim with the VICP; for vulnerable groups and deceased individuals, their legal guardians may apply for compensation. Anyone who received an eligible vaccine within the United States, did so elsewhere but is a US citizen or dependent, or received an American vaccine abroad and returned to the US within 6 months is eligible to apply for VICP compensation.1
About The Authors
Alexandru David is a BS degree candidate in biochemistry and molecular biology at Centre College in Danville, Kentucky.
Joseph L. Fink III, JD, DSC (Hon), BSPHARM, FAPHA, is professor emeritus of pharmacy law and policy and former Kentucky Pharmacists Association Professor of Leadership at the University of Kentucky College of Pharmacy in Lexington.
The most common injury types covered under VICP include anaphylaxis, shoulder injury related to vaccine administration, and vasovagal syncope. An updated list of all covered injuries, vaccines, and accepted time periods for first symptom manifestation can be found on the Health Resources & Services Administration website. Patients should be encouraged to consult this site before filing. Petitioners can engage a lawyer to help file the claim and have VICP pay all associated costs, or they can do so on their own. Additionally, a $400 filing fee must be paid to process the application, but financial assistance is available.1
The limited number of covered vaccines, the strict guidelines of what constitutes a feasible injury, and the lengthy legal process could be reasons why the percentage of successful claims is at only 34%.4 Because of the limited number of court officials trained to deal with VICP claims, many patients also wait up to 3 years for their petitions to be adjudicated, with no guarantee they will be compensated.5 Although the success rate is consistent with other similar programs in Norway, Sweden, or Taiwan, it is much lower than in countries such as Japan, where as many as 80% of petitioners receive compensation. The American VICP offers some of the highest compensation, with a maximum award of $250,000, but it is still lower than in Japan, where a petitioner can receive up to $1 million.4,6